Tavolimab Biosimilar – Anti-TNF- SF4 receptor I mAb – Research Grade

Introduction to Tavolimab Biosimilar – Anti-TNF- SF4 receptor I mAb

Tavolimab Biosimilar is a monoclonal antibody (mAb) that targets the Tumor Necrosis Factor (TNF) – SF4 receptor I, making it a promising therapeutic option for various inflammatory and autoimmune diseases. In this article, we will explore the structure, activity, and potential applications of Tavolimab Biosimilar as a research-grade antibody.

Structure of Tavolimab Biosimilar

Tavolimab Biosimilar is a fully humanized IgG1 monoclonal antibody, meaning it is derived from human cells and has a constant region of IgG1, making it more stable and less likely to elicit an immune response in patients. It has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains, each containing distinct variable and constant regions.

Activity of Tavolimab Biosimilar

Tavolimab Biosimilar binds specifically to the TNF-SF4 receptor I, also known as CD134 or OX40, which is expressed on the surface of activated T cells and other immune cells. By binding to this receptor, Tavolimab Biosimilar inhibits the interaction between TNF-SF4 and its ligand, leading to a decrease in T cell activation and cytokine production.

Furthermore, Tavolimab Biosimilar has been shown to induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which can contribute to the elimination of target cells expressing TNF-SF4 receptor I. This mechanism of action makes Tavolimab Biosimilar a promising candidate for the treatment of various inflammatory and autoimmune diseases.

Applications of Tavolimab Biosimilar

Tavolimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and multiple sclerosis. Its ability to specifically target the TNF-SF4 receptor I and modulate immune responses makes it a potential therapeutic option for these conditions.

In addition, Tavolimab Biosimilar has also been studied as a potential treatment for certain types of cancer, as TNF-SF4 receptor I is overexpressed on the surface of tumor-infiltrating T cells. By inhibiting the activity of these cells, Tavolimab Biosimilar may help to suppress tumor growth and progression.

Research Grade Antibody

Tavolimab Biosimilar is currently being developed as a research-grade antibody, meaning it is intended for use in preclinical and clinical research studies. It is not yet approved for therapeutic use, but its potential applications and promising results in early studies make it an exciting candidate for future treatments.

Conclusion

In summary, Tavolimab Biosimilar is a fully humanized IgG1 monoclonal antibody that specifically targets the TNF-SF4 receptor I, leading to a decrease in T cell activation and cytokine production. It has shown promising results in preclinical and clinical studies for the treatment of various inflammatory and autoimmune diseases, as well as certain types of cancer. As a research-grade antibody, Tavolimab Biosimilar has the potential to contribute to the development of new and effective treatments for these conditions.